A phase I/II for BNT324/DB-1311 with BNT327/PM8002 in patients with SCLC or NSCLC
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs DB-1311 (Primary) ; PM-8002 (Primary)
- Indications Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2025 New trial record
- 14 Jan 2025 According to BioNTech media release, company plans to initiate this trial in 2025